Featured Research

from universities, journals, and other organizations

Brief counseling for drug use doesn't work

Date:
August 5, 2014
Source:
Boston University Medical Center
Summary:
In an effort to stem substance use, the US has invested heavily in the past decade in a brief screening-and-intervention protocol for alcohol and other drugs. But a new study casts doubt on whether that approach, which has proven successful with risky alcohol use, works for illicit drugs.

In an effort to stem substance use, the U.S. has invested heavily in the past decade in a brief screening-and-intervention protocol for alcohol and other drugs.

But a new study by Boston University School of Public Health and School of Medicine researchers casts doubt on whether that approach, which has proven successful with risky alcohol use, works for illicit drugs. The study, published in JAMA, finds that two well established, brief counseling interventions did not reduce the continued use of marijuana, cocaine or opioids -- suggesting that clinicians should "look beyond screening and brief intervention, perhaps to lengthier and more complex . . . care management strategies."

The study, led by Dr. Richard Saitz, chairman of community health sciences at the BU School of Public Health and professor of medicine at the BU School of Medicine, tested the effectiveness of two interventions on 528 adult primary care patients with unhealthy drug use. Participants were assigned to three groups: one that received a 10- to 15-minute structured interview conducted by health educators; a second that received a 30- to 45-minute intervention based on motivational interviewing, with a 20- to 30-minute follow-up session by counselors; and a third that received no brief intervention. All study participants received a written list of substance-use disorder treatment and help resources.

At the beginning of the study, 63 percent of participants reported that their main drug was marijuana, 19 percent cocaine, and 17 percent opioids. All participants reported they were more than casual users, meaning they used drugs at least weekly (or had less frequent use, but with reported consequences). Researchers assessed their drug use at six weeks and six months.

For the primary outcome (number of days of use of the self-identified main drug in the past 30 days), there were no significant differences between the groups. In addition to self-reporting, participants were subjected to hair testing for drugs. There also were no significant, between-group differences at six weeks or six months in drug-use consequences, injection drug use, unsafe sex, or health care utilization.

Saitz said the findings raise questions about the federal government's advocacy -- through the Substance Abuse and Mental Health Services Administration -- of screening and brief interventions to address unhealthy drug use.

"Brief counseling can work for a lot of things, but we found no evidence to support the widespread implementation of universal screening and brief intervention for illicit drug use or prescription drug misuse," Saitz said. "In retrospect, drug use is a complicated problem. While there might have been some hope that something as simple as this would work, it now appears it doesn't."

Saitz and co-authors speculated that screening and brief counseling might work better with unhealthy alcohol use than drugs because risky drinking is socially acceptable and not as complex to reduce.

"People who are using drugs and admit to using drugs are already doing something not socially sanctioned, so getting them to change their behavior may be harder," Saitz said. "Despite many reasons to not use, they are continuing to do so. A few minutes of counseling is not going to change that."

Because each drug is different, he said, a universal intervention is especially difficult. What works to address marijuana use may not work to stop heroin injecting, for example. Prescription drug misuse is particularly complex, as it may involve pain relief, as well as euphoria-seeking behavior or selling of prescribed drugs.

"One-time brief counseling is simply inadequate to address these complexities, even as an initial strategy," Saitz said, adding that even with alcohol use, multiple interventions have been more successful than one-time sessions.

Saitz noted that while primary care physicians may inquire about patients' drug use, most do not screen using optimal tests. He said the study findings should not suggest that screening doesn't work to identify use -- just that one brief intervention is insufficient to reduce it. Identifying drug use is important for reasons beyond aiming to reduce it; it is important to physicians in diagnosis of symptoms and for safe prescribing, he added.

"The message is not that we don't want to address drugs in medical settings -- in fact, I believe we must, just as we address other risk factors and health conditions," he said. "Instead, the message is that this approach is inadequate. We're going to need something more. As doctors, we're going to have to take more responsibility for this problem, the same way we take responsibility for other factors that impact health."

Only 18 percent of the study participants had moderate to severe substance use disorders -- representative of drug use in the typical primary-care clinic population, Saitz said. The rest, who were using drugs with fewer or no consequences, are people for whom effective early identification and intervention could be critical, he said.

The researchers recommended that future trials focus on drug sub-groups (prescription drugs, for example), to gauge whether specialized interventions are effective. They also suggested that trials be conducted using the primary care physician as the interventionist, or establishing a "multi-component" intervention of clinicians and electronic tools.


Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard Saitz, Tibor P. A. Palfai, Debbie M. Cheng, Daniel P. Alford, Judith A. Bernstein, Christine A. Lloyd-Travaglini, Seville M. Meli, Christine E. Chaisson, Jeffrey H. Samet. Screening and Brief Intervention for Drug Use in Primary Care. JAMA, 2014; 312 (5): 502 DOI: 10.1001/jama.2014.7862

Cite This Page:

Boston University Medical Center. "Brief counseling for drug use doesn't work." ScienceDaily. ScienceDaily, 5 August 2014. <www.sciencedaily.com/releases/2014/08/140805163345.htm>.
Boston University Medical Center. (2014, August 5). Brief counseling for drug use doesn't work. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2014/08/140805163345.htm
Boston University Medical Center. "Brief counseling for drug use doesn't work." ScienceDaily. www.sciencedaily.com/releases/2014/08/140805163345.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins